Our Blog

HUTCHMED (CHINA) LIMITED – HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

RNS Number : 4949S Hutchmed (China) Limited 28 August 2026 Press Release HUTCHMED Announces NMPA Approval for ATLED®

HUTCHMED (CHINA) LIMITED – Announcement pursuant to AIM Rule 17 Schedule 2(g) Update

RNS Number : 1249R Hutchmed (China) Limited 18 August 2026 Announcement pursuant to AIM Rule 17 Schedule 2(g) Update

HUTCHMED (CHINA) LIMITED – Hutchmed Reports 2026 Interim Results

RNS Number : 5796O Hutchmed (China) Limited 30 July 2026 HUTCHMED Reports 2026 Interim Results – China product

Hutchison China Meditech Limited – Interim Results

London: Tuesday, July 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs.